Industry coverage tracks the money around peptides: Eli Lilly and Novo Nordisk earnings, pipeline shifts, M&A, IPOs, peptide CDMO capacity, and the telehealth and pharmacy economy that GLP-1s built.
The two stories that keep moving the most market cap: how fast oral GLP-1s reach approval (orforglipron, oral semaglutide, oral wegovy, danuglipron's exit), and what happens to the compounded-peptide channel as the FDA tightens. Hims, Ro, LifeMD, GoodRx, and Amazon Pharmacy have all rerouted distribution in the past year. Behind them, contract manufacturers like Bachem, PolyPeptide, and BASF have been the bottleneck no one talked about until they were.
Stories here name the company, the deal, and the dollars. Earnings, partnership, regulatory hit — whatever moved the share price gets covered.
Samsung Biologics announced Sunday-Monday July 19-20, 2026 an all-cash public tender offer to acquire Switzerland's PolyPeptide Group for CHF 1.46 billion ($1.8 billion) at CHF 44.31 per share, a 40% premium to the undisturbed share price of CHF 31.65. The transaction represents the largest biopharmaceutical M&A in South Korean history. Strategic rationale: PolyPeptide is a global peptide contract development and manufacturing organization (CDMO) with accelerating revenue growth driven by rising client demand for peptide-based GLP-1 therapies for obesity and diabetes. The acquisition expands Samsung Biologics' capabilities beyond monoclonal antibody manufacturing (its historical strength) into peptide therapeutics and adds PolyPeptide's global network spanning Sweden, Belgium, France, the United States, and India, encompassing R&D, development, and commercial manufacturing capabilities. PolyPeptide's Board of Directors unanimously recommends the offer. The largest shareholder has given an irrevocable tender undertaking representing approximately 55.65% of outstanding shares. Samsung Biologics expects to complete the deal by end of 2026. The deal extends the July 2026 peptide-manufacturing consolidation wave alongside Novartis's $1.5 billion Myricx Bio acquisition (ADC payloads, July 6) and Lonza's Nona Biosciences TfR1 blood-brain-barrier deal (July 2).
A Mason-Dixon Polling & Strategy national telephone survey of 1,000 adults commissioned by peptide-education resource Peppies.com released Monday July 20, 2026 documented broad American support for legal peptide compounding access. Field dates: July 13-16, 2026. Sample drawn from a nationwide voter-registration list including landlines and mobile phones, with quotas by state to reflect the adult population. Key finding: 52% of respondents favor being able to obtain peptides through a licensed US pharmacy with a doctor's prescription, 3% oppose, and 45% are unsure. Among the 55% of adults expressing an opinion, adult access is favored by a 19-to-1 ratio. Secondary findings: 60% say the US healthcare system should prioritize preventing illness versus 19% who say it should prioritize treating existing illness, framing the peptide-access debate in the broader public-health prevention conversation. The poll landed days before the FDA Pharmacy Compounding Advisory Committee (PCAC) opens the July 23-24 vote on seven peptides (BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon) at White Oak. The Peppies.com commissioning framing casts the current situation as 'peptide roulette' — patients buying gray-market products of unknown quality because licensed compounding pathways are closed.
Fortune published Monday July 20, 2026 a feature framing the FDA Pharmacy Compounding Advisory Committee's July 23-24 peptide vote as a potential commercial inflection point for the telehealth industry. The article positions Hims & Hers (NYSE: HIMS), Ro, LifeMD (NASDAQ: LFMD), and other GLP-1 telehealth platforms as the natural commercial channels for legal peptide compounding if any of the seven peptides win 503A bulks-list eligibility. The commercial thesis: compounded GLP-1 volume has been the primary telehealth growth driver over 2024-2026, but the April 2025 FDA determination that semaglutide and tirzepatide shortages had resolved (and the April 30, 2026 proposed permanent 503B exclusion) closed the compounding channel for weight-loss demand; a favorable PCAC recommendation followed by FDA rulemaking would open a fresh compoundable-substance category (BPC-157, TB-500, KPV, MOTS-c, and others) that telehealth companies could sell into legally through licensed 503A pharmacies. The Fortune feature ran the same day as the STAT News investigation of LifeMD alleging former-employee patient-safety concerns; the two stories together frame the telehealth channel as simultaneously commercially opportunistic and clinically under scrutiny.
General Bio, a developer of oral GLP-1s and other peptides, has raised $7.4 million and is pursuing a larger follow-on funding round, CEO David Kim told Axios Pro Biotech Deals in an exclusive report published Monday July 20, 2026. The company is one of several new-generation oral peptide startups seeking to compete against the established oral-peptide market, which now spans Novo Nordisk's Wegovy pill (oral semaglutide 25 mg, launched January 2026, over 3 million US prescriptions by June), Merck's LIPFENDRA (enlicitide, oral macrocyclic peptide PCSK9 inhibitor FDA-approved July 16, 2026), and MindRank AI's MDR-001 (AI-designed oral small-molecule GLP-1RA in Phase 3 MOBILE trial in China, $52M Series B closed July 9). The oral peptide category economics are shaped by macrocyclic peptide chemistry (Merck's LIPFENDRA approach) that allows survival through the gastrointestinal tract, permeation-enhancer formulations (Novo's SNAC technology for oral semaglutide), and next-generation delivery platforms including Rani Therapeutics' RaniPill capsule (July 9 collaboration announced with China's PegBio). Seed-stage entrants like General Bio typically position on proprietary chemistry or delivery mechanisms that could enable next-generation peptides beyond the current oral GLP-1 wave.
STAT News published a major investigation Monday July 20, 2026 reporting that LifeMD, a US telehealth company promoted by Novo Nordisk as a partner for Wegovy and Ozempic access, has pushed clinicians to see more patients and dispense GLP-1 prescriptions more rapidly while providing what former workers describe as minimal screening and follow-up. Five former employees and two lawsuits filed by former top leaders allege that providers at LifeMD were pressed to review up to 25 patient cases per hour based only on the electronic intake forms patients themselves filled out, translating to approximately two minutes per case. Novo Nordisk currently lists LifeMD on its website as a partner that offers 'legitimate medicine sourcing and patient support' for people seeking GLP-1 drugs. LifeMD strenuously denies the allegations. The reporting extends the June-July concern set documented by the JAMA secret-shopper study (45 of 49 online sellers wrote semaglutide or tirzepatide prescriptions within a day with limited clinical oversight, July 7 digest coverage) and complements the peptide-telehealth-landscape reporting the site has tracked through 2026. The LifeMD story sits within the sprawling loosely-regulated GLP-1 telehealth industry that experts say has been boosted by Novo Nordisk and Eli Lilly as branded-drug demand expanded through 2025 and 2026.
Q2 2026 earnings season for the peptide-and-obesity big three opens next week. Merck reports Tuesday August 4 at 9:00 AM ET with the LIPFENDRA (enlicitide) FDA approval milestone (July 16) roughly one week old at report time; analyst focus areas include the pricing strategy at $10.50 per tablet ($315 per 30-day supply), the pharmacy-benefit distribution model, and initial payer coverage momentum. Eli Lilly reports Wednesday August 5 before market open; analyst focus areas include Foundayo (orforglipron) first-quarter-out US retail sales (Q1 sales were not yet in the books at the last report), Mounjaro and Zepbound growth versus the Wegovy pill franchise, and TRIUMPH-2 and TRIUMPH-3 readouts for retatrutide expected later in 2026. Novo Nordisk reports Thursday August 6; analyst focus areas include the Wegovy pill uptake beyond the 3 million-prescription milestone documented at ADA 2026 (June), the impact of Novo's price cuts in China and India, the Vivani implant partnership announced July 7, and the response to analyst concerns about the January 2027 Wegovy list price reset to $675 (a 50% cut from current levels). The three earnings prints together are expected to frame the second-half 2026 obesity market trajectory and the competitive positioning of the incretin, amylin, and macrocyclic peptide franchises against each other.
Vera Therapeutics (NASDAQ: VERA) confirmed commercial-launch parameters for TRUTAKNA (atacicept-vymj) following the July 7, 2026 FDA accelerated approval for adults with primary IgA nephropathy at risk of rapid disease progression. List price: $425,000 per year for the recombinant peptide-and-Fc fusion protein (TACI extracellular domain fused to human IgG1 Fc). Sales force: 82 representatives deployed at launch. Distribution: in-channel pharmacy availability within three to four weeks of approval, with insurance coverage under specialty-pharmacy medical benefit pathways given the subcutaneous injection administration. The July 7 accelerated approval was based on the Phase 3 ORIGIN study 36-week urine protein-to-creatinine ratio (UPCR) endpoint (45.7% reduction versus 6.8% for standard of care). Continued FDA approval may be contingent on verification of clinical benefit in the ongoing ORIGIN 3 confirmatory trial, which continues in a placebo-controlled blinded manner to evaluate change in kidney function as measured by estimated glomerular filtration rate (eGFR); results are anticipated in Q3 2026. If the ORIGIN 3 eGFR data hit, TRUTAKNA converts to traditional approval on the harder outcome endpoint.
Merck LIPFENDRA (enlicitide) commercial-launch details firmed up in the days following Thursday July 16, 2026 FDA approval. List price: $10.50 per tablet, or $315 per 30-day supply before insurance discounts, manufacturer support, or pharmacy benefit adjustments. Distribution channel: standard retail and mail-order pharmacies under the pharmacy benefit, which contrasts with Novartis Leqvio (inclisiran) that runs through the medical benefit due to healthcare-provider subcutaneous administration. Expected pharmacy availability: within weeks of approval. The pharmacy benefit pathway matters for real-world access because it eliminates the buy-and-bill logistics that have slowed injectable PCSK9 adoption (Repatha, Praluent, Leqvio) and puts LIPFENDRA on the same pharmacy shelf as statins and cheaper oral non-statin drugs like Nexletol (bempedoic acid) and Zetia (ezetimibe). The macrocyclic peptide's ability to survive gastrointestinal enzymes is what allows the oral delivery model that unlocks the pharmacy-benefit distribution advantage.
Analyst coverage of Merck's LIPFENDRA (enlicitide) FDA approval (Thursday July 16) crystallized Friday. Financial analysts projected LIPFENDRA can generate more than $2 billion in annual sales after a few years on the market. RBC Capital Markets described the label as 'the cleanest in the PCSK9 class,' noting zero contraindications or hypersensitivity warnings, unlike the currently approved injectable PCSK9 competitors (Amgen Repatha/evolocumab, Regeneron/Sanofi Praluent/alirocumab, and Novartis Leqvio/inclisiran). In supporting Phase 3 data, LIPFENDRA statistically outperformed other oral non-statin drugs (Nexletol/bempedoic acid and Zetia/ezetimibe) in adjunctive hypercholesterolemia populations. LIPFENDRA continues to be evaluated in the large cardiovascular outcomes trial CORALreef Outcomes (NCT06008756), which Merck confirmed has completed enrollment with more than 14,500 participants. It is not yet known whether LIPFENDRA reduces cardiovascular morbidity and mortality; the outcomes trial will address that question. Additional data on the safety profile: in CORALreef Lipids, adverse-reaction frequencies were similar between LIPFENDRA and placebo; in CORALreef HeFH the most common adverse reactions more frequent versus placebo were diarrhea (7% vs. 2%) and dizziness (9% vs. 4%), with discontinuation rates similar to placebo.
Swedish biologics company Simris Group announced Thursday July 16, 2026 the appointment of Professor Andreas Pahl, former chief executive of Heidelberg Pharma, as CEO of its German subsidiary Simris Biologics GmbH. Simris Biologics develops microcystin-based ADC payloads derived from naturally occurring cyanobacterial compounds; the payloads are being evaluated for targeted cancer therapies. Pahl brings more than 25 years of experience across drug discovery, translational science, clinical development, and corporate leadership. At Heidelberg Pharma he helped build the company into a leading ADC developer and led advancement of the amanitin-based ADC platform (payload derived from the death cap mushroom Amanita phalloides); under his leadership the platform advanced into the clinic and was validated in a Phase 1 study. The Simris move extends the July 2026 payload-and-linker chemistry deal wave anchored by Novartis's July 6 $1.5 billion acquisition of UK biotech Myricx Bio (N-myristoyltransferase inhibitor NMTi payload platform), Lonza's July 2 acquisition of Nona Biosciences' TfR1 blood-brain-barrier delivery technology, and SOTIO's July 14 FDA Fast Track Designation for the CDH17-targeting SOT109 ADC in metastatic colorectal cancer.
Roche (SIX: ROG) presented new Elecsys plasma phosphorylated-tau 217 (pTau217) blood test performance data at AAIC 2026 in London (July 12-15, 2026) covering both primary care and secondary care settings. The Elecsys pTau217 in vitro diagnostic assay, developed in collaboration with Eli Lilly, received CE Mark certification on May 12, 2026 as an amyloid-pathology rule-in and rule-out test for adults presenting with symptoms of cognitive decline. The same high and low cutoffs of the blood test can be used across primary care (family physicians, general internists) and secondary care (memory clinics, neurology specialty practice) to rule in or rule out amyloid pathology, which simplifies the diagnostic pathway substantially compared with amyloid PET imaging or lumbar puncture. The AAIC 2026 presentations evaluated Elecsys pTau217 performance across both care settings and add real-world diagnostic evidence to the tau-blood-test infrastructure that Eli Lilly's Samantha Burnham anchored earlier in the week with the rule-in-versus-amyloid-PET data set. Roche's AAIC 2026 program spanned undiagnosed Alzheimer's pathology in cardiovascular patients, ApoE4-dependent CETP-inhibitor dose response, and Alzheimer's diagnostic-and-therapeutic integration.
Veru Inc. (NASDAQ: VERU), a late clinical-stage biopharmaceutical company focused on cardiometabolic and inflammatory diseases, presented at the 4th Annual Obesity & Weight Loss Drug Development Summit in Boston, Massachusetts on Tuesday July 14, 2026. Gary Barnette, PhD, Chief Scientific Officer, led the pre-conference workshop 'Moving Beyond BMI & Weight-Loss Endpoints to Advance the Regulatory Frontier & Redefine Clinical Success With the FDA' at 1:30 PM ET. On Wednesday July 15 at 4:20 PM ET, Chairman, President and CEO Mitchell Steiner, MD will present 'Combating Sarcopenic Obesity in Geriatrics by Combining GLP-1s With Selective Androgen Receptor Modulators (SARMs) to Prevent Muscle Loss.' Veru's lead asset enobosarm is a selective androgen receptor modulator (SARM) in Phase 2b development for muscle-loss prevention in older patients receiving GLP-1 receptor agonists for weight loss. The sarcopenic-obesity thesis directly addresses a widely documented GLP-1 side effect: approximately 25-40% of GLP-1-associated weight loss is lean muscle mass rather than fat, particularly in older patients. Veru's approach pairs the GLP-1 with a SARM to preserve muscle while maintaining fat loss.
Pfizer (NYSE: PFE) named Danna Breen Vice President and head of obesity discovery on Monday July 13, 2026, following the departure of longtime scientific leader Kendra Bence. Bence had led internal medicine research across metabolic dysfunction-associated steatohepatitis (formerly known as NASH) and obesity discovery at Pfizer's Kendall Square research site for more than a decade, and described the role as 'the absolute privilege of my career' when announcing her exit. Breen advanced through multiple roles at Pfizer including Research Associate, Fellow, Senior Principal Scientist, Principal Scientist, and Senior Scientist, working on novel obesity drug targets and research collaborations. The role transition arrives as Pfizer's obesity portfolio expands substantially: the monthly GLP-1 receptor agonist berobenatide (PF-3944) is advancing through 10 planned Phase 3 studies presented at ADA 2026 in June, and the November 2025 $10 billion Metsera acquisition brought in the amylin peptide MET-233i (positive Phase 1 data supporting monthly dosing). Endpoints News concurrently reported AI startup Xaira making its own leadership adjustments as the sector's talent map continues to reshape.
CNBC Healthy Returns and the Peterson Health Technology Institute (PHTI) documented Wednesday July 8, 2026 that employer coverage of GLP-1 drugs for obesity has held steady at 36% year-over-year despite the Medicare GLP-1 Bridge launching on July 1 and putting downward pressure on the payer landscape. Mercer survey data shows 60% of employers cover GLP-1s for diabetes only, 36% cover for both diabetes and weight loss, 3% don't cover them at all, and 2% are not sure. Rather than expanding coverage, employers pursued alternative approaches: 27% steer workers to direct-to-consumer cash platforms (such as LillyDirect, NovoCare Pharmacy, and telehealth intermediaries), while 21% push workers to use FSA, HSA, or integrated HRA dollars. GoodRx data show the uninsured share for Zepbound rose 18% year-over-year, leaving over 114 million Americans with no commercial coverage for the drug; 88% of those who do have coverage face additional requirements like prior authorization. GLP-1 drugs accounted for 11.4% of annual claims for employers covering them in 2026, up from 6.9% in 2023, sustaining the affordability tension that has kept coverage stuck.
Gallup released Tuesday July 7, 2026 poll results (survey conducted May-June 2026 with 5,000+ respondents across all 50 states and DC) showing 1 in 9 US adults (11%) now take a GLP-1 medication for weight loss. That share tripled from 3% in the 2024 survey and rose from 8% in 2025. The US adult obesity rate, which peaked at 39.9% in 2022, has drifted down to 36.4% in 2026, a statistically significant decline that inversely tracks the rise in GLP-1 use. Awareness of GLP-1 drugs for weight loss climbed from 80% in 2024 to 91% in 2026. Diagnosis of diabetes held steady after 15 years of slow increase in prior surveys. Follow-up coverage ran through Wednesday-Friday (Foreign Policy Journal, Forbes' Zachary Folk, Medscape, Fox 7 Austin, Bakery & Snacks) framing the results as the first large-population evidence that GLP-1 uptake is bending the US obesity curve. Payer analyst commentary tracked in parallel: employers continue steering workers toward cash-pay GLP-1 platforms as sticker prices stay high and adherence remains a concern (roughly two-thirds of non-T2D GLP-1 patients discontinue within one year).
Novartis announced Monday July 6, 2026 that it has entered into a definitive agreement to acquire UK biotech Myricx Bio for up to $1.5 billion ($1.1 billion cash upfront plus potential milestone payments) to advance next-generation ADC payload innovation. Myricx Bio developed a first-in-class N-myristoyltransferase inhibitor (NMTi) payload platform. NMT is an enzyme that maintains the function of certain proteins inside cells, and cancer cells rely on it to grow and survive; blocking NMT with a payload delivered via ADC disrupts those processes directly inside tumor cells. Myricx's two lead assets target B7-H3 and HER2 across multiple solid-tumor settings. The transaction is expected to close in H2 2026 subject to customary closing conditions including regulatory approvals. The deal extends the payload-and-linker chemistry infrastructure that peptide-drug conjugates (PDCs), ADCs, and adjacent bioconjugate modalities share. Novo Holdings (through its portfolio company backing of Myricx) and Sofinnova Partners were among the pre-deal investors. Endpoints News framed the transaction as another 2026 signal that payload innovation, not antibody targeting alone, is driving competitive differentiation in the next-generation ADC race.
Lonza announced Thursday July 2, 2026 that it has acquired rights to Nona Biosciences' transferrin receptor 1 (TfR1) blood-brain barrier (BBB) technology and expanded its strategic collaboration with Nona to develop next-generation BBB delivery platforms. The technology uses single-domain VHH antibodies that bind TfR1, a receptor expressed on the cells lining the blood-brain barrier, to shuttle attached payloads into the brain. The platform can deploy as an immunoglobulin G (IgG) fusion or through conjugation with therapeutic molecules using Lonza's GlycoConnect bioconjugation technology. Preclinical data show that Nona's TfR1-binding VHH improved brain delivery versus a leading industry benchmark in a relevant transgenic model. Financial terms were not disclosed. Under the agreement, Lonza will immediately make the technology available to CNS drug developers while continuing to collaborate with Nona on future BBB platforms. The deal fits Lonza's CDMO-facing strategy of combining GS Gene Expression System capabilities with GlycoConnect chemistry to give customers new tools for CNS therapeutic candidates — including peptide-and-conjugate CNS programs that have historically been limited by BBB penetration.
MindRank AI, a Chinese clinical-stage biotech built around a proprietary Molecule Arts Platform (MAP) integrating biology, chemistry, computation, experimental evidence, and clinical learning, announced Thursday July 9, 2026 the completion of a $52 million Series B financing led by a group of institutional and healthcare funds. The company's lead program, MDR-001, is an AI-designed oral small-molecule GLP-1 receptor agonist that entered Phase 3 development in China in 2025 with the initiation of the MOBILE Phase 3 trial enrolling approximately 750 participants with overweight or obesity. The trial evaluates 52-week efficacy and safety. MindRank reports cumulative R&D investment from project initiation through the start of Phase 3 in China of approximately $23 million, with the program advancing from concept to Phase 3 in roughly 4.5 years. The financing extends the oral-GLP-1 competitive set beyond Eli Lilly's Foundayo (orforglipron), Novo Nordisk's Wegovy pill (oral semaglutide 25 mg), and Structure Therapeutics' aleniglipron. Anticipated commercial launch: within two to three years.